J Morser Selected Research

Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)

6/2018	Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.
6/2015	Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
4/2013	Thrombin-activatable fibrinolysis inhibitor (TAFI) is enhanced in major trauma patients without infectious complications.
1/2013	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) levels are decreased in patients with trauma-induced coagulopathy.
11/2010	High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice.
4/2010	Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
1/2008	Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Morser Research Topics

Disease

7	Thrombosis (Thrombus) 06/2018 - 05/2000
3	Inflammation (Inflammations) 06/2018 - 04/2013
2	Wounds and Injuries (Trauma) 04/2013 - 01/2013
2	Fibrosis (Cirrhosis) 03/2012 - 01/2008
2	Venous Thrombosis (Deep-Vein Thrombosis) 09/2003 - 12/2001
1	Hemolytic-Uremic Syndrome 01/2018
1	Sepsis (Septicemia) 06/2015
1	Asthma (Bronchial Asthma) 10/2013
1	Diabetic Nephropathies (Diabetic Nephropathy) 03/2012
1	Proteinuria 03/2012
1	Neoplasms (Cancer) 11/2010
1	Carcinogenesis 11/2010
1	Vascular Remodeling 04/2010
1	Pulmonary Hypertension 04/2010
1	Acute Lung Injury 12/2009
1	Crush Injuries 12/2004
1	Vascular System Injuries 09/2003
1	Unstable Angina 12/2001
1	Hemorrhage 10/2001
1	Aneurysm (Aneurysms) 10/2001
1	Abdominal Aortic Aneurysm 10/2001
1	Vascular Diseases (Vascular Disease) 08/2001

Drug/Important Bio-Agent (IBA)

7	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 06/2018 - 01/2008
4	FidexabanIBA 12/2004 - 08/2001
4	Factor Xa (Coagulation Factor Xa)IBA 12/2004 - 08/2001
3	CytokinesIBA 03/2012 - 12/2009
2	Complement System Proteins (Complement)IBA 01/2018 - 11/2010
2	Thrombin FDA Link 10/2013 - 08/2001
2	Proteins (Proteins, Gene)FDA Link 03/2012 - 12/2009
2	Protein CIBA 03/2012 - 12/2009
2	Apolipoproteins E (ApoE)IBA 11/2010 - 10/2001
2	ApolipoproteinsIBA 11/2010 - 10/2001
2	Enoxaparin (Lovenox)FDA LinkGeneric 12/2004 - 12/2001
1	Lysine Carboxypeptidase (Carboxypeptidase N)IBA 06/2018
1	cobra venom factorIBA 01/2018
1	Complement C3a (Complement 3a)IBA 06/2015
1	HirudinsIBA 10/2013
1	ThrombomodulinIBA 10/2013
1	argatroban (MPQA)FDA Link 10/2013
1	AntithrombinsIBA 10/2013
1	OvalbuminIBA 10/2013
1	NitrogenIBA 03/2012
1	CollagenIBA 03/2012
1	CreatinineIBA 03/2012
1	Hydroxyproline (4 Hydroxyproline)IBA 03/2012
1	Streptozocin (Streptozotocin)FDA Link 03/2012
1	Urea (Carbamide)FDA LinkGeneric 03/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2012
1	Protein SIBA 12/2009
1	Fibrinolysin FDA Link 01/2008
1	Pharmaceutical PreparationsIBA 12/2004
1	Thromboplastin (Tissue Factor)IBA 09/2003
1	CopperIBA 09/2003
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2001
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 12/2001
1	enoxaparin sodium FDA LinkGeneric 12/2001
1	Angiotensin IIIBA 10/2001
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2001
1	ElastinIBA 10/2001
1	Peptide Hydrolases (Proteases)FDA Link 08/2001
1	Blood Coagulation Factors (Coagulation Factor)IBA 08/2001
1	cyclopropapyrroloindoleIBA 05/2000

Therapy/Procedure

2	Therapeutics 03/2012 - 12/2009
1	Ligation 06/2015
1	Punctures 06/2015
1	Catheters 09/2003
1	Thrombolytic Therapy 04/2001
1	Intravenous Administration 05/2000